1,308 Shares in Insulet Co. (NASDAQ:PODD) Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI acquired a new stake in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,308 shares of the medical instruments supplier's stock, valued at approximately $341,000.

A number of other institutional investors and hedge funds have also made changes to their positions in PODD. Independent Advisor Alliance increased its stake in shares of Insulet by 20.8% during the fourth quarter. Independent Advisor Alliance now owns 1,378 shares of the medical instruments supplier's stock worth $360,000 after purchasing an additional 237 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in Insulet by 22.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 15,114 shares of the medical instruments supplier's stock worth $3,946,000 after buying an additional 2,736 shares during the last quarter. Taika Capital LP purchased a new stake in Insulet during the 4th quarter worth approximately $361,000. AlphaQuest LLC raised its holdings in shares of Insulet by 12,800.0% during the fourth quarter. AlphaQuest LLC now owns 1,290 shares of the medical instruments supplier's stock valued at $337,000 after acquiring an additional 1,280 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in shares of Insulet by 0.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 13,028 shares of the medical instruments supplier's stock valued at $3,401,000 after acquiring an additional 59 shares in the last quarter.

Insulet Trading Up 2.4 %

Shares of NASDAQ PODD traded up $6.19 during trading on Monday, reaching $261.63. The stock had a trading volume of 780,292 shares, compared to its average volume of 690,624. The business's 50-day moving average price is $272.54 and its 200-day moving average price is $255.32. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a market cap of $18.37 billion, a P/E ratio of 45.19, a PEG ratio of 3.62 and a beta of 1.29.

Remove Ads

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. On average, equities research analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Eric Benjamin sold 12,394 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.47% of the company's stock.

Wall Street Analysts Forecast Growth

PODD has been the subject of several research reports. Citigroup boosted their price target on Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Raymond James reissued an "outperform" rating and issued a $328.00 price target (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Canaccord Genuity Group upped their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Finally, StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.